1
|
Wei JD, Kim JH. Two distinct forms of human BLT2: long-form and short-form BLT2. Front Cell Dev Biol 2023; 11:1288373. [PMID: 37954206 PMCID: PMC10637354 DOI: 10.3389/fcell.2023.1288373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Accepted: 10/11/2023] [Indexed: 11/14/2023] Open
Abstract
BLT2 is a low-affinity leukotriene B4 receptor that plays an essential role in the pathogenesis of various inflammatory diseases, including asthma and cancer. BLT2 is minimally expressed in a normal internal environment but is overexpressed in a stress-induced inflammatory environment. Recent research indicated that human BLT2 has two distinct forms. Although their functions are likely to be different, very few studies investigated these differences. Therefore, this paper will discuss about the two distinct forms of human BLT2; the short-form of BLT2 and the long-form of BLT2.
Collapse
Affiliation(s)
- Jun-Dong Wei
- Department of Basic Medical Science, Medical College, Taizhou University, Taizhou, China
| | - Jae-Hong Kim
- Division of Life Sciences, College of Life Sciences, Korea University, Seoul, Republic of Korea
| |
Collapse
|
2
|
Hébert MPA, Selka A, Lebel AA, Doiron JA, Isabel Chiasson A, Gauvin VL, Matthew AJ, Hébert MJG, Doucet MS, Joy AP, Barnett DA, Touaibia M, Surette ME, Boudreau LH. Caffeic acid phenethyl ester analogues as selective inhibitors of 12-lipoxygenase product biosynthesis in human platelets. Int Immunopharmacol 2023; 121:110419. [PMID: 37295028 DOI: 10.1016/j.intimp.2023.110419] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 05/17/2023] [Accepted: 05/30/2023] [Indexed: 06/11/2023]
Abstract
The inflammatory response is an essential process for the host defence against pathogens. Lipid mediators are important in coordinating the pro-inflammatory and pro-resolution phases of the inflammatory process. However, unregulated production of these mediators has been associated with chronic inflammatory diseases such as arthritis, asthma, cardiovascular diseases, and several types of cancer. Therefore, it is not surprising that enzymes implicated in the production of these lipid mediators have been targeted for potential therapeutic approaches. Amongst these inflammatory molecules, the 12-hydroxyeicosatetraenoic acid (12(S)-HETE) is abundantly produced in several diseases and is primarily biosynthesized via the platelet's 12-lipoxygenase (12-LO) pathway. To this day, very few compounds selectively inhibit the 12-LO pathway, and most importantly, none are currently used in the clinical settings. In this study, we investigated a series of polyphenol analogues of natural polyphenols that inhibit the 12-LO pathway in human platelets without affecting other normal functions of the cell. Using an ex vivo approach, we found one compound that selectively inhibited the 12-LO pathway, with IC50 values as low as 0.11 µM, with minimal inhibition of other lipoxygenase or cyclooxygenase pathways. More importantly, our data show that none of the compounds tested induced significant off-target effects on either the platelet's activation or its viability. In the continuous search for specific and better inhibitors targeting the regulation of inflammation, we characterized two novel inhibitors of the 12-LO pathway that could be promising for subsequent in vivo studies.
Collapse
Affiliation(s)
- Mathieu P A Hébert
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada; New Brunswick Center for Precision Medicine, 27 Providence Street, Moncton, New Brunswick E1C 8X3, Canada
| | - Ayyoub Selka
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada
| | - Andréa A Lebel
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada; New Brunswick Center for Precision Medicine, 27 Providence Street, Moncton, New Brunswick E1C 8X3, Canada
| | - Jérémie A Doiron
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada; New Brunswick Center for Precision Medicine, 27 Providence Street, Moncton, New Brunswick E1C 8X3, Canada
| | - Audrey Isabel Chiasson
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada
| | - Vanessa L Gauvin
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada; New Brunswick Center for Precision Medicine, 27 Providence Street, Moncton, New Brunswick E1C 8X3, Canada
| | - Alexis J Matthew
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada; New Brunswick Center for Precision Medicine, 27 Providence Street, Moncton, New Brunswick E1C 8X3, Canada
| | - Martin J G Hébert
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada
| | - Marco S Doucet
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada
| | - Andrew P Joy
- Atlantic Cancer Research Institute, Moncton, 27 Providence Street, Moncton, New Brunswick E1C 8X3, Canada
| | - David A Barnett
- Atlantic Cancer Research Institute, Moncton, 27 Providence Street, Moncton, New Brunswick E1C 8X3, Canada
| | - Mohamed Touaibia
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada.
| | - Marc E Surette
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada; New Brunswick Center for Precision Medicine, 27 Providence Street, Moncton, New Brunswick E1C 8X3, Canada
| | - Luc H Boudreau
- Department of Chemistry and Biochemistry, Université de Moncton, 18 Antonine-Maillet Avenue, Moncton, New Brunswick E1A 3E9, Canada; New Brunswick Center for Precision Medicine, 27 Providence Street, Moncton, New Brunswick E1C 8X3, Canada.
| |
Collapse
|
3
|
CSNK1A1, KDM2A, and LTB4R2 Are New Druggable Vulnerabilities in Lung Cancer. Cancers (Basel) 2021; 13:cancers13143477. [PMID: 34298691 PMCID: PMC8305418 DOI: 10.3390/cancers13143477] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 07/01/2021] [Accepted: 07/06/2021] [Indexed: 11/24/2022] Open
Abstract
Simple Summary The main histological subtypes of lung cancer are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). NSCLC is further subdivided into squamous-cell carcinoma (SCC) and adenocarcinoma (AD). Despite the recent introduction of innovative therapies, lung cancer is still the first cause of cancer-related human death, indicating that the discovery of new therapeutic targets is still a compelling need for this disease. In the present work, we performed a functional genomics analysis on different lung cancer histotypes, combining data derived from different omics resources with in vitro validation. Through this approach, we identified and validated CSNK1A1, KDMA2, and LTB4R2 as new druggable vulnerabilities in lung cancer. These results open new possibilities for the development of innovative therapies for lung cancer patients. Abstract Lung cancer is the leading cause of cancer-related human death. It is a heterogeneous disease, classified in two main histotypes, small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), which is further subdivided into squamous-cell carcinoma (SCC) and adenocarcinoma (AD) subtypes. Despite the introduction of innovative therapeutics, mainly designed to specifically treat AD patients, the prognosis of lung cancer remains poor. In particular, available treatments for SCLC and SCC patients are currently limited to platinum-based chemotherapy and immune checkpoint inhibitors. In this work, we used an integrative approach to identify novel vulnerabilities in lung cancer. First, we compared the data from a CRISPR/Cas9 dependency screening performed in our laboratory with Cancer Dependency Map Project data, essentiality comprising information on 73 lung cancer cell lines. Next, to identify relevant therapeutic targets, we integrated dependency data with pharmacological data and TCGA gene expression information. Through this analysis, we identified CSNK1A1, KDM2A, and LTB4R2 as relevant druggable essentiality genes in lung cancer. We validated the antiproliferative effect of genetic or pharmacological inhibition of these genes in two lung cancer cell lines. Overall, our results identified new vulnerabilities associated with different lung cancer histotypes, laying the basis for the development of new therapeutic strategies.
Collapse
|
4
|
Biringer RG. A review of non-prostanoid, eicosanoid receptors: expression, characterization, regulation, and mechanism of action. J Cell Commun Signal 2021; 16:5-46. [PMID: 34173964 DOI: 10.1007/s12079-021-00630-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Accepted: 06/07/2021] [Indexed: 11/29/2022] Open
Abstract
Eicosanoid signaling controls a wide range of biological processes from blood pressure homeostasis to inflammation and resolution thereof to the perception of pain and to cell survival itself. Disruption of normal eicosanoid signaling is implicated in numerous disease states. Eicosanoid signaling is facilitated by G-protein-coupled, eicosanoid-specific receptors and the array of associated G-proteins. This review focuses on the expression, characterization, regulation, and mechanism of action of non-prostanoid, eicosanoid receptors.
Collapse
Affiliation(s)
- Roger G Biringer
- College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, 5000 Lakewood Ranch Blvd, Bradenton, FL, 34211, USA.
| |
Collapse
|
5
|
Matsumoto Y, Matsuya Y, Nagai K, Amagase K, Saeki K, Matsumoto K, Yokomizo T, Kato S. Leukotriene B 4 Receptor Type 2 Accelerates the Healing of Intestinal Lesions by Promoting Epithelial Cell Proliferation. J Pharmacol Exp Ther 2020; 373:1-9. [PMID: 31941716 DOI: 10.1124/jpet.119.263145] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 01/02/2020] [Indexed: 12/19/2022] Open
Abstract
Leukotriene B4 receptor type 2 (BLT2) is a low-affinity leukotriene B4 receptor that is highly expressed in intestinal epithelial cells. Previous studies demonstrated the protective role of BLT2 in experimentally induced colitis. However, its role in intestinal lesion repair is not fully understood. We investigated the role of BLT2 in the healing of indomethacin-induced intestinal lesions in mice. There was no significant different between wild-type (WT) and BLT2-deficient (BLT2KO) mice in terms of the development of indomethacin-induced intestinal lesions. However, healing of these lesions was significantly impaired in BLT2KO mice compared with WT mice. In contrast, transgenic mice with intestinal epithelium-specific BLT2 overexpression presented with superior ileal lesion healing relative to WT mice. An immunohistochemical study showed that the number of Ki-67-proliferative cells was markedly increased during the healing of intestinal lesions in WT mice but significantly attenuated in BLT2KO mice. Exposure of cultured mouse intestinal epithelial cells to CAY10583, a BLT2 agonist, promoted wound healing and cell proliferation in a concentration-dependent manner. Nevertheless, these responses were abolished under serum-free conditions. The CAY10583-induced proliferative effect was also negated by Go6983, a protein kinase C (PKC) inhibitor, U-73122, a phospholipase C (PLC) inhibitor, LY255283, a BLT2 antagonist, and pertussis toxin that inhibits G protein-coupled receptor signaling via Gi/o proteins. Thus, BLT2 plays an important role in intestinal wound repair. Moreover, this effect is mediated by the promotion of epithelial cell proliferation via the Gi/o protein-dependent and PLC/PKC signaling pathways. The BLT2 agonists are potential therapeutic agents for the treatment of intestinal lesions. SIGNIFICANCE STATEMENT: The healing of indomethacin-induced Crohn's disease-like intestinal lesions was impaired in mice deficient in low-affinity leukotriene B4 receptor type 2 (BLT2). They presented with reduced epithelial cell proliferation during the healing. In contrast, healing was promoted in mice overexpressing intestinal epithelial BLT2. In cultured intestinal epithelial cells, the BLT2 agonist CAY10583 substantially accelerated wound repair by enhancing cell proliferation rather than migration. Thus, BLT2 plays an important role in the intestinal lesions via acceleration of epithelial cell proliferation.
Collapse
Affiliation(s)
- Yui Matsumoto
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Yukiko Matsuya
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Kano Nagai
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Kikuko Amagase
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Kazuko Saeki
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Kenjiro Matsumoto
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Takehiko Yokomizo
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| | - Shinichi Kato
- Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Kyoto, Japan (Yui.M, Yuk.M., K.N., K.A., K.M., S.K.); Laboratory of Pharmacology and Pharmacotherapy, College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (K.A.); and Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo, Japan (K.S., T.Y.)
| |
Collapse
|
6
|
Ko KY, Lee JH, Jang JK, Jin Y, Kang H, Kim IY. S-Glutathionylation of mouse selenoprotein W prevents oxidative stress-induced cell death by blocking the formation of an intramolecular disulfide bond. Free Radic Biol Med 2019; 141:362-371. [PMID: 31299423 DOI: 10.1016/j.freeradbiomed.2019.07.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Revised: 06/20/2019] [Accepted: 07/08/2019] [Indexed: 12/15/2022]
Abstract
Mouse selenoprotein W (SELENOW) is a small protein containing a selenocysteine (Sec, U) and four cysteine (Cys, C) residues. The Sec residue in SELENOW is located within the conserved CXXU motif corresponding to the CXXC redox motif of thioredoxin (Trx). It is known that glutathione (GSH) binds to SELENOW and that this binding is involved in protecting cells from oxidative stress. However, the regulatory mechanisms controlling the glutathionylation of SELENOW in oxidative stress are unclear. In this study, using purified recombinant SELENOW in which Sec13 was changed to Cys, we found that SELENOW was glutathionylated at Cys33 and that this S-glutathionylation was enhanced by oxidative stress. We also found that the S-glutathionylation of SELENOW at Cys33 in HEK293 cells was due to glutathione S-transferase Pi (GSTpi) and that this modification was reversed by glutaredoxin1 (Grx1). In addition to the disulfide bond between the Cys10 and Cys13 of SELENOW, a second disulfide bond was formed between Cys33 and Cys87 under oxidative stress conditions. The second disulfide bond was reduced by Trx1, but the disulfide bond between Cys10 and Cys13 was not. The second disulfide bond was also reduced by glutathione, but the disulfide bond in the CXXC motif was not. The second disulfide bond of the mutant SELENOW, in which Cys37 was replaced with Ser, was formed at a much lower concentration of hydrogen peroxide than the wild type. We also observed that Cys37 was required for S-glutathionylation, and that S-glutathionylated SELENOW containing Cys37 protected the cells from oxidative stress. Furthermore, the SELENOW (C33, 87S) mutant, which could not form the second disulfide bond, also showed antioxidant activity. Taken together, these results indicate that GSTpi-mediated S-glutathionylation of mouse SELENOW at Cys33 is required for the protection of cells in conditions of oxidative stress, through inhibition of the formation of the second disulfide bond.
Collapse
Affiliation(s)
- Kwan Young Ko
- Laboratory of Cellular and Molecular Biochemistry, Department of Life Sciences, Korea University, Seoul, 02841, South Korea
| | - Jea Hwang Lee
- Center for Human Genetic Research, Massachusetts General Hospital, 185 Cambridge ST, Boston, MA, 02114-2790, USA
| | - Jun Ki Jang
- Laboratory of Cellular and Molecular Biochemistry, Department of Life Sciences, Korea University, Seoul, 02841, South Korea
| | - Yunjung Jin
- Laboratory of Cellular and Molecular Biochemistry, Department of Life Sciences, Korea University, Seoul, 02841, South Korea
| | - Hyunwoo Kang
- Laboratory of Cellular and Molecular Biochemistry, Department of Life Sciences, Korea University, Seoul, 02841, South Korea
| | - Ick Young Kim
- Laboratory of Cellular and Molecular Biochemistry, Department of Life Sciences, Korea University, Seoul, 02841, South Korea.
| |
Collapse
|